Poster 42
May 24, 2023
1 min read
Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 and STOP-HS2 Phase 3 Studies
Martina L. Porter, MD, Antonio Martorell, MD, PhD, Christopher J. Sayed, MD, Falk G. Bechara, MD, Hadar Lev-Tov, MD, MAS, Jennifer L. Hsiao, MD, John W. Frew, MBBS, MMed, MSc, PhD, Christos C. Zouboulis, MD, PhD, Joslyn S. Kirby, MD, MS, MEd, Huiling Zhen, PhD, Leandro L. Santos, MS
